Cargando…
Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report
Mucopolysaccharidosis type I S (MPS IS) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the IDUA gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Enzyme replacement therapy (ERT) reduces lysosomal storage in the liver and improves clinical manifestatio...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424730/ https://www.ncbi.nlm.nih.gov/pubmed/36052356 http://dx.doi.org/10.3389/fped.2022.973193 |
_version_ | 1784778286859026432 |
---|---|
author | Vasilevska, Lauma Auzenbaha, Madara Grinfelde, Ieva Skangale, Anita |
author_facet | Vasilevska, Lauma Auzenbaha, Madara Grinfelde, Ieva Skangale, Anita |
author_sort | Vasilevska, Lauma |
collection | PubMed |
description | Mucopolysaccharidosis type I S (MPS IS) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the IDUA gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Enzyme replacement therapy (ERT) reduces lysosomal storage in the liver and improves clinical manifestations. To date, there are no published reports of tuberculosis (TB) treatment in MPS IS patients receiving ERT and as such it is not known whether both conditions can be treated simultaneously. Here, we report the case of a 14-year-old male with MPS IS receiving ERT with laronidase who was diagnosed with a latent TB infection after being in contact with a multi-drug-resistant TB patient. He received prophylactic TB treatment with moxifloxacin for 6 months. No complications were reported and there has been no active TB disease. Our case report demonstrates that TB and MPS IS can be treated simultaneously without serious adverse effects. |
format | Online Article Text |
id | pubmed-9424730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94247302022-08-31 Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report Vasilevska, Lauma Auzenbaha, Madara Grinfelde, Ieva Skangale, Anita Front Pediatr Pediatrics Mucopolysaccharidosis type I S (MPS IS) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the IDUA gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Enzyme replacement therapy (ERT) reduces lysosomal storage in the liver and improves clinical manifestations. To date, there are no published reports of tuberculosis (TB) treatment in MPS IS patients receiving ERT and as such it is not known whether both conditions can be treated simultaneously. Here, we report the case of a 14-year-old male with MPS IS receiving ERT with laronidase who was diagnosed with a latent TB infection after being in contact with a multi-drug-resistant TB patient. He received prophylactic TB treatment with moxifloxacin for 6 months. No complications were reported and there has been no active TB disease. Our case report demonstrates that TB and MPS IS can be treated simultaneously without serious adverse effects. Frontiers Media S.A. 2022-08-16 /pmc/articles/PMC9424730/ /pubmed/36052356 http://dx.doi.org/10.3389/fped.2022.973193 Text en Copyright © 2022 Vasilevska, Auzenbaha, Grinfelde and Skangale. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Vasilevska, Lauma Auzenbaha, Madara Grinfelde, Ieva Skangale, Anita Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report |
title | Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report |
title_full | Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report |
title_fullStr | Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report |
title_full_unstemmed | Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report |
title_short | Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report |
title_sort | treatment of latent tuberculosis in a child with mucopolysaccharidosis type i receiving enzyme replacement therapy: a case report |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424730/ https://www.ncbi.nlm.nih.gov/pubmed/36052356 http://dx.doi.org/10.3389/fped.2022.973193 |
work_keys_str_mv | AT vasilevskalauma treatmentoflatenttuberculosisinachildwithmucopolysaccharidosistypeireceivingenzymereplacementtherapyacasereport AT auzenbahamadara treatmentoflatenttuberculosisinachildwithmucopolysaccharidosistypeireceivingenzymereplacementtherapyacasereport AT grinfeldeieva treatmentoflatenttuberculosisinachildwithmucopolysaccharidosistypeireceivingenzymereplacementtherapyacasereport AT skangaleanita treatmentoflatenttuberculosisinachildwithmucopolysaccharidosistypeireceivingenzymereplacementtherapyacasereport |